A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Study Identifier:
AEB-21
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Epidermolysis Bullosa
Study Drug
- Drug: Filsuvez
Date
Dec 2024 - Nov 2031
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A
Requirements Information
Healthy Volunteers
No
Protocol Summary
In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for up to 5 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.
Study Locations
Location
Status
Location
CHU de Toulouse, Hôpital Larrey
Toulouse, France
Status
Recruiting